SHANGHAI, July 21, 2025 /PRNewswire/ -- CPHI & PMEC China 2025 concluded in June with a record-breaking 109,056 attendees, underscoring strong demand within China's thriving pharma industry.
Building on this success, CPHI & PMEC Shenzhen 2025 will take place from 1–3 September 2025 at Shenzhen Convention & Exhibition Center (SZCEC), addressing the growing demand for access to South China's key pharma markets.
As a key gateway to the Guangdong-Hong Kong-Macau Greater Bay Area, Shenzhen is positioned to drive pharma innovation. The region's health industry GDP is projected to surpass 2 trillion CNY by 2028 and reach 2.5 trillion to 3 trillion CNY by 2030, offering unparalleled opportunities for growth and collaboration.
CPHI & PMEC Shenzhen is set to achieve remarkable growth in 2025, doubling its size to 30,000 sqm of show floor and featuring over 600 selected exhibiting companies from various sectors of the pharmaceutical industry, including pharma ingredients, excipients, biotech, contract services, pharma machinery, packaging machinery, packaging materials and more. The event will expand product zones for natural supply, finished dosage, clean technology and laboratory instruments. A new 'Beauty & Cosmetics Supply Chain Zone' will showcase products and foster collaboration in this rapidly growing sector.
During the exhibition, over 20 high-level forums will bring together regulatory authorities, academic experts, and corporate leaders to deliver in-depth analysis of policy shifts, technological breakthroughs, and emerging market dynamics. Key topics include new drug R&D, API process optimisation, CXO collaborations, emerging markets strategy, nutrition and health food development, natural ingredients and functional food development, injectable medical aesthetics innovation, pharma packaging solutions, pharma manufacturing 4.0, pharmaceutical engineering and more.
To forge strategic partnerships, exclusive Hosted Buyer Matchmaking and Plant visit will be organized. These initiatives will facilitate meaningful interactions between suppliers and international buyers with specific purchasing demand.
With its strategic location and curated focus, CPHI & PMEC Shenzhen 2025 is set to redefine pharma innovation in South China. The event offers unparalleled opportunities for networking, knowledge exchange, and collaboration, empowering attendees to unlock new growth horizons across Asia's thriving pharmaceutical sector.
Register as a visitor before 1 August to enjoy complimentary VIP benefits:
https://reg.cphi-china.cn/en/express-ticketing/shenzhenvip
For more information, please visit:
https://www.cphi.com/china/en-gb/home.html
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
CPHI & PMEC Shenzhen 2025: Unlocking New Opportunities in Asia and the Greater Bay Area
TAIPEI, Dec. 31, 2025 /PRNewswire/ -- ARTERY Technology (Cayman) Corporation (Stock Code: 6907; hereinafter referred to as "ARTERY-KY"), a leading designer of 32-bit microcontrollers (MCUs), is scheduled to be listed on the Taipei Exchange (TPEx) under the Semiconductor Industry category in January 2026. The Company held its first pre-IPO investor conference on December 30 (Tuesday) at the Grand Hyatt Taipei, where it presented its competitive strengths and future business outlook to investors.
As a subsidiary of Faraday Technology, ARTERY-KY focuses on the development of high-end 32-bit MCUs. Leveraging ARM® Cortex®-M4 cores with an industry-leading maximum clock speed of up to 288 MHz, the Company delivers exceptional performance. In addition to successfully entering the supply chains of leading global brands, ARTERY-KY has established itself as a key contributor in the China market through localized technical advantages, serving as an important partner in regional supply chain transformation.
ARTERY-KY possesses comprehensive technical capabilities spanning core architecture design to application integration. Its end-market applications cover a wide range of fields, including industrial and motor control, consumer electronics, commercial applications, and vertical industries such as medical, IoT, communications, and automotive electronics. With strengths in high performance, low power consumption, superior integration, and high cost-effectiveness, the Company continues to expand into emerging applications such as drones, robotics, and edge AI, demonstrating strong market competitiveness and growth momentum.
In terms of financial performance, ARTERY-KY recorded revenue of NT$1.635 billion in 2024, representing a year-on-year increase of over 60%, with earnings per share (EPS) of NT$1.67. Revenue for the first three quarters of 2025 reached NT$1.234 billion, maintaining a high level and setting a new historical high for the same period, indicating that the Company has emerged from the inventory adjustment cycle. With continued optimization of its product mix, gross margin rebounded significantly to 33.84%. Net profit after tax for the first three quarters totaled NT$70.52 million, with basic EPS of NT$1.38, marking a 56% year-on-year increase and reflecting solid profitability. As multiple new application projects enter mass production and major customer orders continue to grow steadily, the market expects further optimization of the product portfolio in 2026, driving simultaneous growth in revenue and earnings.
Looking ahead, ARTERY-KY has outlined three major growth strategies. First, it will establish a comprehensive MCU foundation spanning M0 to M85 to build a highly compatible ecosystem. Second, it will expand its ASIC-based customized MCU services to help customers rapidly develop application-specific chips. Finally, the Company will aggressively pursue edge AI opportunities by collaborating with UMC and Faraday Technology, utilizing the most advanced 28-nanometer embedded Flash process to develop an intelligent inference platform. Through a strategy focused on breadth, depth, and forward-looking innovation, ARTERY-KY aims to fully activate its semiconductor growth engine.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Emerging MCU Force ARTERY-KY to Be Listed on TPEx in January 2026, Driving High-Performance Growth Through MCU, Customization, and Edge AI
